ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous Tumor-infiltrating Lymphocytes HS-IT101

Also written as “HS-IT101 Injection” and “HS-IT101 monotherapy”.

Its studies are mostly in Melanoma · Carcinoma, Renal Cell, led by 2 companies.

Furthest: phase 1, since Apr 15, 20253 company-led studies, 2 open or runningNext primary completion: Aug 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hangzhou Huasai Biomedicine21 open or runningphase 1since Apr 15, 2025Apr 15, 2025Aug 2028phase 1 · NCT07770802
Qingdao Sino-Cell Biomedicine11 open or runningphase 1since Mar 19, 2024Mar 19, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 19, 2024First study: phase 1 study in Solid TumorNew to Qingdao Sino-Cell BiomedicineQingdao Sino-Cell Biomedicine · NCT06342336 · 44 planned · China
  2. Apr 15, 2025Hangzhou Huasai Biomedicine’s first study: phase 1 study in Advanced MelanomaNew to Hangzhou Huasai BiomedicineHangzhou Huasai Biomedicine · NCT06941818 · 5 enrolled · China
  3. Aug 13, 2026Phase 1 study in Carcinoma, Renal CellHangzhou Huasai Biomedicine · NCT07770802 · 15 planned · China

Ahead

  1. Aug 2028Primary completion: phase 1 study in Carcinoma, Renal CellHangzhou Huasai Biomedicine · NCT07770802

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07770802Carcinoma, Renal Cell · China1RecruitingHangzhou Huasai BiomedicineAug 202815
NCT06941818Advanced Melanoma · China1CompletedHangzhou Huasai BiomedicineFeb 20, 20265
NCT06342336Solid Tumor · China1RecruitingQingdao Sino-Cell BiomedicineMar 31, 202644

How it is read

Names in the registry

  • “HS-IT101 Injection”, 2 entries
  • “HS-IT101 monotherapy”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.